JP2018529671A5 - - Google Patents

Download PDF

Info

Publication number
JP2018529671A5
JP2018529671A5 JP2018511491A JP2018511491A JP2018529671A5 JP 2018529671 A5 JP2018529671 A5 JP 2018529671A5 JP 2018511491 A JP2018511491 A JP 2018511491A JP 2018511491 A JP2018511491 A JP 2018511491A JP 2018529671 A5 JP2018529671 A5 JP 2018529671A5
Authority
JP
Japan
Prior art keywords
compound
salt
pharmaceutically acceptable
phosphoryl
dioxo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018511491A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018529671A (ja
JP6743135B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2016/049873 external-priority patent/WO2017040766A1/en
Publication of JP2018529671A publication Critical patent/JP2018529671A/ja
Publication of JP2018529671A5 publication Critical patent/JP2018529671A5/ja
Application granted granted Critical
Publication of JP6743135B2 publication Critical patent/JP6743135B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018511491A 2015-09-02 2016-09-01 抗ウィルス性テトラヒドロフラン誘導体 Expired - Fee Related JP6743135B2 (ja)

Applications Claiming Priority (21)

Application Number Priority Date Filing Date Title
US201562213378P 2015-09-02 2015-09-02
US62/213,378 2015-09-02
US201562242136P 2015-10-15 2015-10-15
US62/242,136 2015-10-15
US201562253426P 2015-11-10 2015-11-10
US62/253,426 2015-11-10
US201662294449P 2016-02-12 2016-02-12
US62/294,449 2016-02-12
US201662296801P 2016-02-18 2016-02-18
US62/296,801 2016-02-18
US201662321538P 2016-04-12 2016-04-12
US62/321,538 2016-04-12
US201662327087P 2016-04-25 2016-04-25
US62/327,087 2016-04-25
US201662351038P 2016-06-16 2016-06-16
US62/351,038 2016-06-16
US201662363640P 2016-07-18 2016-07-18
US62/363,640 2016-07-18
US201662375029P 2016-08-15 2016-08-15
US62/375,029 2016-08-15
PCT/US2016/049873 WO2017040766A1 (en) 2015-09-02 2016-09-01 Anti-viral tetrahydrofurane derivatives

Publications (3)

Publication Number Publication Date
JP2018529671A JP2018529671A (ja) 2018-10-11
JP2018529671A5 true JP2018529671A5 (enExample) 2019-11-21
JP6743135B2 JP6743135B2 (ja) 2020-08-19

Family

ID=56926317

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018511491A Expired - Fee Related JP6743135B2 (ja) 2015-09-02 2016-09-01 抗ウィルス性テトラヒドロフラン誘導体

Country Status (7)

Country Link
US (2) US9676797B2 (enExample)
EP (1) EP3344642A1 (enExample)
JP (1) JP6743135B2 (enExample)
CN (1) CN108350016B (enExample)
CA (1) CA2997170A1 (enExample)
MX (1) MX2018002707A (enExample)
WO (1) WO2017040766A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107709344B (zh) * 2015-05-01 2022-07-15 共晶制药股份有限公司 用于治疗黄病毒科病毒和癌症的核苷类似物
EP3344642A1 (en) * 2015-09-02 2018-07-11 AbbVie Inc. Anti-viral tetrahydrofurane derivatives
WO2018093717A1 (en) * 2016-11-17 2018-05-24 Abbvie Inc. Compositions and methods for treating hcv infection
US10435429B2 (en) 2017-10-03 2019-10-08 Nucorion Pharmaceuticals, Inc. 5-fluorouridine monophosphate cyclic triester compounds
KR102708995B1 (ko) 2018-01-10 2024-09-23 누코리온 파마슈티컬스, 인코포레이티드. 포스포르(포스포론)아미다타세탈 및 포스프(온)아탈세탈 화합물
US11427550B2 (en) 2018-01-19 2022-08-30 Nucorion Pharmaceuticals, Inc. 5-fluorouracil compounds
CN109762040A (zh) * 2019-01-14 2019-05-17 歌礼生物制药(杭州)有限公司 一种核苷类ns5b聚合酶抑制剂的制备方法
AU2020315394A1 (en) 2019-07-17 2022-02-17 Nucorion Pharmaceuticals, Inc. Cyclic deoxyribonucleotide compounds
CN115768778A (zh) 2020-04-21 2023-03-07 配体药物公司 苄氧基磷酸(膦酸)酯化合物
EP4143199B1 (en) 2020-04-21 2025-11-19 Ligand Pharmaceuticals, Inc. Nucleotide prodrug compounds
US12274700B1 (en) 2020-10-30 2025-04-15 Accencio LLC Methods of treating symptoms of coronavirus infection with RNA polymerase inhibitors

Family Cites Families (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4526988A (en) 1983-03-10 1985-07-02 Eli Lilly And Company Difluoro antivirals and intermediate therefor
US5246924A (en) 1987-09-03 1993-09-21 Sloan-Kettering Institute For Cancer Research Method for treating hepatitis B virus infections using 1-(2'-deoxy-2'-fluoro-beta-D-arabinofuranosyl)-5-ethyluracil
SE8802687D0 (sv) 1988-07-20 1988-07-20 Astra Ab Nucleoside derivatives
US6060592A (en) 1990-01-11 2000-05-09 Isis Pharmaceuticals, Inc. Pyrimidine nucleoside compounds and oligonucleoside compounds containing same
US6060542A (en) 1997-05-16 2000-05-09 Shell Oil Company Bitumen compositions and a process for their preparation
AU2787199A (en) 1998-02-25 1999-09-15 Emory University 2'-fluoronucleosides
MY164523A (en) 2000-05-23 2017-12-29 Univ Degli Studi Cagliari Methods and compositions for treating hepatitis c virus
US6787526B1 (en) 2000-05-26 2004-09-07 Idenix Pharmaceuticals, Inc. Methods of treating hepatitis delta virus infection with β-L-2′-deoxy-nucleosides
JP5230052B2 (ja) 2000-05-26 2013-07-10 イデニクス(ケイマン)リミテツド フラビウイルスおよびペスチウイルス治療のための方法および組成物
US6596700B2 (en) 2000-05-26 2003-07-22 Idenix Pharmaceuticals Inc. Methods of treating hepatitis delta virus infection with β-L-2'-deoxy-nucleosides
US20030008841A1 (en) 2000-08-30 2003-01-09 Rene Devos Anti-HCV nucleoside derivatives
AU2001296542B2 (en) * 2000-10-02 2007-10-25 Emory University Triptolide analogs for the treatment of autoimmune and inflammatory disorders
ATE491459T1 (de) 2000-10-18 2011-01-15 Pharmasset Inc Modifizierte nukleoside zur behandlung von virusinfektionen und abnormaler zellulärer proliferation
US7105499B2 (en) 2001-01-22 2006-09-12 Merck & Co., Inc. Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase
DZ3487A1 (fr) 2001-01-22 2002-07-25 Merck Sharp & Dohme Derives de nucleoside comme inhibiteurs de l'arn polymerase virale d'arn-dependant
US8481712B2 (en) 2001-01-22 2013-07-09 Merck Sharp & Dohme Corp. Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase
WO2003026589A2 (en) 2001-09-28 2003-04-03 Idenix (Cayman) Limited Methods and compositions for treating hepatitis c virus using 4'-modified nucleosides
JP2005533777A (ja) 2002-06-17 2005-11-10 メルク エンド カムパニー インコーポレーテッド Rna抗ウイルス剤としての炭素環ヌクレオシドアナログ
WO2004000858A2 (en) 2002-06-21 2003-12-31 Merck & Co., Inc. Nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase
US7608600B2 (en) 2002-06-28 2009-10-27 Idenix Pharmaceuticals, Inc. Modified 2′ and 3′-nucleoside prodrugs for treating Flaviviridae infections
AP2005003213A0 (en) 2002-06-28 2005-03-31 Univ Cagliari 2'-C-methyl-3'-O-L-valine ester ribofuranosyl cytidine for treatment of flaviviridae infections.
US7824851B2 (en) 2002-11-15 2010-11-02 Idenix Pharmaceuticals, Inc. 2′-branched nucleosides and Flaviviridae mutation
MXPA05006230A (es) 2002-12-12 2005-09-20 Idenix Cayman Ltd Proceso para la produccion de nucleosidos ramificados-2'.
WO2004084453A2 (en) * 2003-03-20 2004-09-30 Microbiologica Quimica E Farmaceutica Ltd. METHODS OF MANUFACTURE OF 2'-DEOXY-β-L-NUCLEOSIDES
CN100503628C (zh) 2003-05-30 2009-06-24 法莫赛特股份有限公司 修饰的氟化核苷类似物
GB0317009D0 (en) 2003-07-21 2003-08-27 Univ Cardiff Chemical compounds
WO2006063149A1 (en) 2004-12-09 2006-06-15 Regents Of The University Of Minnesota Nucleosides with antiviral and anticancer activity
US7250416B2 (en) 2005-03-11 2007-07-31 Supergen, Inc. Azacytosine analogs and derivatives
WO2006121820A1 (en) 2005-05-05 2006-11-16 Valeant Research & Development Phosphoramidate prodrugs for treatment of viral infection
US7964580B2 (en) 2007-03-30 2011-06-21 Pharmasset, Inc. Nucleoside phosphoramidate prodrugs
PA8852101A1 (es) 2008-12-08 2010-07-27 Medivir Ab Nucleótidos uracil ciclopropílicos
US8618076B2 (en) 2009-05-20 2013-12-31 Gilead Pharmasset Llc Nucleoside phosphoramidates
TWI598358B (zh) 2009-05-20 2017-09-11 基利法瑪席特有限責任公司 核苷磷醯胺
US8937150B2 (en) 2009-06-11 2015-01-20 Abbvie Inc. Anti-viral compounds
UA118080C2 (uk) 2009-06-11 2018-11-26 Еббві Айрленд Анлімітед Компані Противірусні сполуки
US9790252B2 (en) 2009-07-01 2017-10-17 Cornell University 2-fluorinated riboses and arabinoses and methods of use and synthesis
EP2789615B1 (en) * 2009-08-11 2017-05-03 Bristol-Myers Squibb Company Azaindazoles as Btk kinase modulators and use thereof
US9700560B2 (en) 2009-11-16 2017-07-11 University Of Georgia Research Foundation, Inc. 2′-fluoro-6′-methylene carbocyclic nucleosides and methods of treating viral infections
CL2011000718A1 (es) * 2010-03-31 2012-04-09 Gilead Pharmasset Llc Proceso para la preparacion de compuestos fosforados enantiomericos.
WO2012040126A1 (en) * 2010-09-22 2012-03-29 Alios Biopharma, Inc. Substituted nucleotide analogs
PT3042910T (pt) 2010-11-30 2019-04-16 Gilead Pharmasset Llc 2'-espiro-nucleósidos para utilização na terapia da hepatite c
US9156874B2 (en) * 2011-01-03 2015-10-13 Nanjing Molecular Research, Inc. Double-liver-targeting phosphoramidate and phosphonoamidate prodrugs
EP2691409B1 (en) 2011-03-31 2018-02-21 Idenix Pharmaceuticals LLC. Compounds and pharmaceutical compositions for the treatment of viral infections
EA201391519A1 (ru) * 2011-04-13 2014-03-31 Мерк Шарп И Доум Корп. 2'-замещенные нуклеозидные производные и способы их применения для лечения вирусных заболеваний
WO2012142523A2 (en) * 2011-04-13 2012-10-18 Gilead Sciences, Inc. 1'-substituted pyrimidine n-nucleoside analogs for antiviral treatment
US8889159B2 (en) 2011-11-29 2014-11-18 Gilead Pharmasset Llc Compositions and methods for treating hepatitis C virus
US20130143835A1 (en) * 2011-12-05 2013-06-06 Medivir Ab HCV Polymerase Inhibitors
EA024297B1 (ru) * 2011-12-20 2016-09-30 Рибосайенс Ллк 2',4'-дифтор-2'-метилзамещенные нуклеозидные производные в качестве ингибиторов репликации рнк вируса гепатита с
SG11201403086YA (en) * 2011-12-20 2014-07-30 Hoffmann La Roche 4'-azido, 3'-fluoro substituted nucleoside derivatives as inhibitors of hcv rna replication
CN104640444B (zh) * 2012-06-16 2016-12-14 河南美泰宝生物制药有限公司 双肝脏靶向氨基磷酸酯和氨基膦酸酯前药
CN102751200B (zh) 2012-06-29 2015-06-10 京东方科技集团股份有限公司 薄膜晶体管、阵列基板及其制造方法
US20140065101A1 (en) * 2012-08-31 2014-03-06 Novartis Ag 2'-Branched Nucleosides for Treatment of Viral Infections
CN111848711A (zh) 2012-10-08 2020-10-30 埃迪尼克斯医药有限责任公司 用于hcv感染的2′-氯核苷类似物
AR092959A1 (es) 2012-10-17 2015-05-06 Merck Sharp & Dohme Derivados de nucleosidos 2-metil sustituidos y metodos de uso de los mismos para el tratamiento de enfermedades virales
US9211300B2 (en) 2012-12-19 2015-12-15 Idenix Pharmaceuticals Llc 4′-fluoro nucleosides for the treatment of HCV
CN110684067A (zh) 2012-12-21 2020-01-14 艾丽奥斯生物制药有限公司 取代的核苷和核苷酸
US10034893B2 (en) 2013-02-01 2018-07-31 Enanta Pharmaceuticals, Inc. 5, 6-D2 uridine nucleoside/tide derivatives
WO2014169278A1 (en) 2013-04-12 2014-10-16 Achillion Pharmaceuticals, Inc. Highly active nucleoside derivative for the treatment of hcv
US9815864B2 (en) 2013-06-26 2017-11-14 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
UA117375C2 (uk) * 2013-09-04 2018-07-25 Медівір Аб Інгібітори полімерази hcv
EP3043803B1 (en) 2013-09-11 2022-04-27 Emory University Nucleotide and nucleoside compositions and their uses
AU2014331863C1 (en) 2013-10-11 2019-05-16 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
EP3057976A1 (en) * 2013-10-17 2016-08-24 Medivir Ab Hcv polymerase inhibitors
US20160280729A1 (en) * 2013-11-20 2016-09-29 Idenix Pharmaceuticals Llc Cyclopentane and cyclopentene nucleoside analogs for the treatment of hcv
WO2015081297A1 (en) 2013-11-27 2015-06-04 Idenix Pharmaceuticals, Inc. 2'-dichloro and 2'-fluoro-2'-chloro nucleoside analogues for hcv infection
EP3102188A4 (en) * 2014-02-05 2017-07-12 Merck Sharp & Dohme Corp. Novel disintegration systems for pharmaceutical dosage forms
WO2015161137A1 (en) 2014-04-16 2015-10-22 Idenix Pharmaceuticals, Inc. 3'-substituted methyl or alkynyl nucleosides for the treatment of hcv
EP3134423A4 (en) 2014-04-24 2017-11-29 Cocrystal Pharma, Inc. 2' -disubstituted nucleoside analogs for treatment of the flaviviridae family of viruses and cancer
CN107108683A (zh) 2014-10-31 2017-08-29 共晶制药股份有限公司 用于治疗黄病毒科病毒和癌症的2’,2’‑二卤代核苷类似物
CN107709344B (zh) * 2015-05-01 2022-07-15 共晶制药股份有限公司 用于治疗黄病毒科病毒和癌症的核苷类似物
EP3344642A1 (en) * 2015-09-02 2018-07-11 AbbVie Inc. Anti-viral tetrahydrofurane derivatives

Similar Documents

Publication Publication Date Title
JP2018529671A5 (enExample)
RU2016138735A (ru) Соединения дигидропиримидина и их применение в фармацевтических препаратах
EA022127B1 (ru) Ингибиторы вируса гепатита с
JP2020183410A5 (enExample)
JP2019510796A5 (enExample)
JP2020504733A5 (enExample)
RU2016122908A (ru) Соединения дигидропиримидина и их применение в фармацевтических препаратах
JP2011511840A5 (enExample)
JP2010525056A5 (enExample)
JP2024156774A5 (enExample)
HRP20151075T1 (hr) Kristalni (s)-izopropil 2-(((s)-(((2r,3r,4r,5r)-5-(2,4-diokso-3,4-dihidropirimidin-1-(2h)-il)-4-fluoro-3-hidroksi-4-metiltetrahidrofuran-2-il)metoksi)(fenoksi)fosforil)amino) propanoat
JP2009535352A5 (enExample)
JP2016538313A5 (enExample)
JP2020507589A5 (enExample)
JP2017523225A5 (enExample)
NZ582089A (en) Antiviral Combination of elvitegravir, lopinavir and optionally ritonavir
JP2015514806A5 (enExample)
JP2014513110A5 (enExample)
JP2015529652A5 (enExample)
JP2010532747A5 (enExample)
JP2021500394A5 (enExample)
JP2016523974A5 (enExample)
JP2010500414A5 (enExample)
JP2010504346A5 (enExample)
JP2008513516A5 (enExample)